Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
Corporate Governance
Resources

News Releases

Year

Jul 20 / 26

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Jul 15 / 26

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Jul 06 / 26

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Jul 06 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Jun 12 / 26

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Jun 02 / 26

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20 / 26

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

May 18 / 26

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

May 15 / 26

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 9 of 19

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio